Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASBP Aspire Biopharma	$0.54 +3.5%	$0.36	$0.22 ▼ $15.80	$26.64M	0.79	10.09 million shs	47.10 million shs
CMMB Chemomab Therapeutics	$0.89 -3.5%	$1.10	$0.87 ▼ $2.55	$16.71M	0.52	225,345 shs	72,197 shs
COCP Cocrystal Pharma	$1.50 -1.6%	$1.61	$1.12 ▼ $3.26	$15.34M	2.07	42,481 shs	19,888 shs
GLTO Galecto	$3.35 -0.9%	$3.44	$2.01 ▼ $14.88	$4.42M	1.35	118,811 shs	6,585 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASBP Aspire Biopharma	+11.38%	+30.28%	+27.21%	+51,979,900.00%	+51,979,900.00%
CMMB Chemomab Therapeutics	-1.29%	-4.18%	-16.55%	-32.50%	-25.97%
COCP Cocrystal Pharma	-0.65%	-9.52%	-5.59%	+4.11%	-20.42%
GLTO Galecto	+0.45%	+0.30%	-6.25%	+13.29%	-76.76%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASBP Aspire Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CMMB Chemomab Therapeutics	3.2793 of 5 stars	3.5	5.0	0.0	0.0	2.4	1.7	0.6
COCP Cocrystal Pharma	3.0449 of 5 stars	3.5	5.0	0.0	0.0	2.7	1.7	0.0
GLTO Galecto	3.6432 of 5 stars	3.5	5.0	0.0	0.0	2.8	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASBP Aspire Biopharma	0.00	N/A	N/A	N/A
CMMB Chemomab Therapeutics	3.00	Buy	$8.50	862.63% Upside
COCP Cocrystal Pharma	3.00	Buy	$6.00	297.35% Upside
GLTO Galecto	3.00	Buy	$10.00	200.30% Upside

Current Analyst Ratings Breakdown

Latest GLTO, ASBP, CMMB, and COCP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/20/2025	COCP Cocrystal Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $6.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASBP Aspire Biopharma	N/A	N/A	N/A	N/A	($0.19) per share	N/A
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	$0.51 per share	N/A
COCP Cocrystal Pharma	N/A	N/A	N/A	N/A	$0.52 per share	N/A
GLTO Galecto	N/A	N/A	N/A	N/A	$7.26 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASBP Aspire Biopharma	-$12.54M	N/A	0.00	∞	N/A	N/A	N/A	-737.96%	N/A
CMMB Chemomab Therapeutics	-$13.94M	-$0.59	N/A	N/A	N/A	N/A	-94.71%	-76.53%	N/A
COCP Cocrystal Pharma	-$17.50M	-$1.24	N/A	N/A	N/A	N/A	-144.12%	-102.85%	N/A
GLTO Galecto	-$21.44M	-$13.13	N/A	N/A	N/A	N/A	-115.70%	-95.42%	11/7/2025 (Estimated)

Latest GLTO, ASBP, CMMB, and COCP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CMMB Chemomab Therapeutics	-$0.20	-$0.09	+$0.11	-$0.09	N/A	N/A
8/14/2025	Q2 2025	COCP Cocrystal Pharma	-$0.30	-$0.20	+$0.10	-$0.20	N/A	N/A
8/13/2025	Q2 2025	ASBP Aspire Biopharma	N/A	-$0.04	N/A	-$0.04	N/A	N/A
8/5/2025	Q2 2025	GLTO Galecto	N/A	-$2.60	N/A	-$2.60	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASBP Aspire Biopharma	N/A	N/A	N/A	N/A	N/A
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	N/A
COCP Cocrystal Pharma	N/A	N/A	N/A	N/A	N/A
GLTO Galecto	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASBP Aspire Biopharma	N/A	0.09	0.09
CMMB Chemomab Therapeutics	N/A	7.42	5.33
COCP Cocrystal Pharma	N/A	3.69	4.57
GLTO Galecto	N/A	4.96	4.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASBP Aspire Biopharma	19.17%
CMMB Chemomab Therapeutics	46.05%
COCP Cocrystal Pharma	6.72%
GLTO Galecto	14.20%

Insider Ownership

Company	Insider Ownership
ASBP Aspire Biopharma	48.00%
CMMB Chemomab Therapeutics	11.91%
COCP Cocrystal Pharma	28.14%
GLTO Galecto	10.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASBP Aspire Biopharma	N/A	49.53 million	25.75 million	N/A
CMMB Chemomab Therapeutics	20	18.86 million	16.61 million	Not Optionable
COCP Cocrystal Pharma	10	10.26 million	7.37 million	Not Optionable
GLTO Galecto	40	1.32 million	1.18 million	Optionable

GLTO, ASBP, CMMB, and COCP Headlines

Recent News About These Companies

Galecto, Inc. Focuses on Oncology and Liver Disease

August 6, 2025 | tipranks.com

Galecto Reports Second Quarter 2025 Operating and Financial Results

August 5, 2025 | globenewswire.com

Galecto, Inc. (GLTO) stock price, news, quote & history - Yahoo Finance

June 26, 2025 | sg.finance.yahoo.com

Galecto, Inc. Reports First Quarter 2025 Financial Results and Progress on AML Treatment Development

May 10, 2025 | nasdaq.com

Galecto, Inc.: Galecto Reports First Quarter 2025 Operating and Financial Results

May 9, 2025 | finanznachrichten.de

Galecto Reports First Quarter 2025 Operating and Financial Results

May 8, 2025 | globenewswire.com

Galecto (GLTO)

April 12, 2025 | es.investing.com

Galecto, Inc. Focuses on Oncology and Liver Diseases

April 3, 2025 | tipranks.com

Galecto trading halted, volatility trading pause

March 26, 2025 | markets.businessinsider.com

Galecto, Inc. Completes Strategic Review, Acquires Global Rights to GB3226 for Oncology and Liver Disease Focus

March 19, 2025 | quiverquant.comQ

Galecto Reports Full-Year 2024 Financial Results

March 19, 2025 | globenewswire.com

Galecto stock hits 52-week low at $4.39 amid market challenges

February 12, 2025 | msn.com

Galecto to Participate in Upcoming Investor Conferences

February 6, 2025 | globenewswire.com

When (GLTO) Moves Investors should Listen

January 1, 2025 | news.stocktradersdaily.comN

(GLTO) Technical Pivots with Risk Controls

November 29, 2024 | news.stocktradersdaily.comN

Galecto (NASDAQ:GLTO) Stock, Option Chain

November 15, 2024 | benzinga.com

Galecto (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

November 14, 2024 | zacks.com

Galecto, Inc. Announces Strategic Shift and Financial Overview

November 2, 2024 | markets.businessinsider.com

Galecto, Inc.’s Strategic Shift to Oncology and Liver Diseases: Navigating Risks and Opportunities

November 2, 2024 | tipranks.com

Galecto reports Q3 EPS ($3.39) vs ($7.50)

November 1, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLTO, ASBP, CMMB, and COCP Company Descriptions

Aspire Biopharma NASDAQ:ASBP

$0.54 +0.02 (+3.46%)

As of 03:58 PM Eastern

Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.

Chemomab Therapeutics NASDAQ:CMMB

$0.89 -0.03 (-3.49%)

Closing price 03:49 PM Eastern

Extended Trading

$0.89 0.00 (0.00%)

As of 04:10 PM Eastern

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Cocrystal Pharma NASDAQ:COCP

$1.49 -0.03 (-2.24%)

As of 04:00 PM Eastern

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

Galecto NASDAQ:GLTO

$3.35 -0.03 (-0.92%)

Closing price 03:58 PM Eastern

Extended Trading

$3.32 -0.03 (-0.84%)

As of 04:01 PM Eastern

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time